BACKGROUND AND OBJECTIVES: Chronic kidney disease (CKD) conveys high mortality rates. Soluble TNF-like weak inducer of apoptosis (sTWEAK) and long pentraxin 3 (PTX3) are predictors of mortality in dialysis patients and determinants of endothelial dysfunction. Now, we hypothesize that both sTWEAK and PTX3 act as biomarkers of cardiovascular outcomes in nondialysis CKD patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Cross-sectional analysis in which flow-mediated dilation (FMD) and intima-media thickness (IMT) were assessed in 257 nondialysis stage 1 to 5 CKD patients (mean age, 52 ± 12 years; 130 men), together with biochemical measurements and sTWEAK and PTX3 assessments. Patients were followed for cardiovascular outcomes. RESULTS: PTX3 and IMT increased, whereas FMD and sTWEAK decreased across CKD stages (P<0.001 for all). Both PTX3 and sTWEAK appeared as strong determinants of FMD in multivariate analysis. The univariate associations of sTWEAK and PTX3 with IMT were dependent on estimated GFR. After a median of 39 months (range, 2 to 43 months), 22 fatal and 57 nonfatal cardiovascular events occurred. In a Cox model excluding PTX3, decreasing sTWEAK concentration was associated with increased risk of cardiovascular events independently of basic confounders (age, gender, estimated GFR, C reactive protein, diabetes, and cardiovascular comorbidity) and FMD. In a model excluding sTWEAK, circulating levels of PTX3 were directly associated with cardiovascular outcomes independently of basic confounders, but this association was lost after adjustment for FMD. CONCLUSIONS: Both PTX3 and sTWEAK levels associated with the endothelial dysfunction observed with progressive kidney failure. Additionally, both biomarkers impacted the predictability of cardiovascular outcomes.
BACKGROUND AND OBJECTIVES:Chronic kidney disease (CKD) conveys high mortality rates. Soluble TNF-like weak inducer of apoptosis (sTWEAK) and long pentraxin 3 (PTX3) are predictors of mortality in dialysis patients and determinants of endothelial dysfunction. Now, we hypothesize that both sTWEAK and PTX3 act as biomarkers of cardiovascular outcomes in nondialysis CKDpatients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Cross-sectional analysis in which flow-mediated dilation (FMD) and intima-media thickness (IMT) were assessed in 257 nondialysis stage 1 to 5 CKDpatients (mean age, 52 ± 12 years; 130 men), together with biochemical measurements and sTWEAK and PTX3 assessments. Patients were followed for cardiovascular outcomes. RESULTS:PTX3 and IMT increased, whereas FMD and sTWEAK decreased across CKD stages (P<0.001 for all). Both PTX3 and sTWEAK appeared as strong determinants of FMD in multivariate analysis. The univariate associations of sTWEAK and PTX3 with IMT were dependent on estimated GFR. After a median of 39 months (range, 2 to 43 months), 22 fatal and 57 nonfatal cardiovascular events occurred. In a Cox model excluding PTX3, decreasing sTWEAK concentration was associated with increased risk of cardiovascular events independently of basic confounders (age, gender, estimated GFR, C reactive protein, diabetes, and cardiovascular comorbidity) and FMD. In a model excluding sTWEAK, circulating levels of PTX3 were directly associated with cardiovascular outcomes independently of basic confounders, but this association was lost after adjustment for FMD. CONCLUSIONS: Both PTX3 and sTWEAK levels associated with the endothelial dysfunction observed with progressive kidney failure. Additionally, both biomarkers impacted the predictability of cardiovascular outcomes.
Authors: Juan A Moreno; Tiphaine Dejouvencel; Julien Labreuche; David M Smadja; Michaël Dussiot; José L Martin-Ventura; Jesús Egido; Pascale Gaussem; Joseph Emmerich; Jean-Baptiste Michel; Luis M Blanco-Colio; Olivier Meilhac Journal: Arterioscler Thromb Vasc Biol Date: 2010-03-18 Impact factor: 8.311
Authors: Mahmut Ilker Yilmaz; Juan Jesús Carrero; Jose Luis Martín-Ventura; Alper Sonmez; Mutlu Saglam; Turgay Celik; Halil Yaman; Mujdat Yenicesu; Tayfun Eyileten; Juan Antonio Moreno; Jesús Egido; Luis Miguel Blanco-Colio Journal: Clin J Am Soc Nephrol Date: 2010-04-29 Impact factor: 8.237
Authors: Begoña Muñoz-García; Juan Antonio Moreno; Oscar López-Franco; Ana Belén Sanz; José Luis Martín-Ventura; Julia Blanco; Aniela Jakubowski; Linda C Burkly; Alberto Ortiz; Jesús Egido; Luis Miguel Blanco-Colio Journal: Arterioscler Thromb Vasc Biol Date: 2009-09-24 Impact factor: 8.311
Authors: Mahmut Ilker Yilmaz; Juan Jesús Carrero; Alberto Ortiz; Jose Luis Martín-Ventura; Alper Sonmez; Mutlu Saglam; Halil Yaman; Mujdat Yenicesu; Jesús Egido; Luis Miguel Blanco-Colio Journal: Clin J Am Soc Nephrol Date: 2009-10-09 Impact factor: 8.237
Authors: Juan A Moreno; Begoña Muñoz-García; Jose L Martín-Ventura; Julio Madrigal-Matute; Josune Orbe; Jose A Páramo; Luis Ortega; Jesús Egido; Luis M Blanco-Colio Journal: Atherosclerosis Date: 2009-05-04 Impact factor: 5.162
Authors: Mahmut Ilker Yilmaz; Abdul Rashid Qureshi; Juan Jesus Carrero; Mutlu Saglam; Mohamed E Suliman; Kayser Caglar; Tayfun Eyileten; Alper Sonmez; Yusuf Oguz; Abdulgaffar Vural; Mujdat Yenicesu; Jonas Axelsson Journal: Am J Nephrol Date: 2009-12-31 Impact factor: 3.754
Authors: Ana B Sanz; Maria Dolores Sanchez-Niño; Maria Concepcion Izquierdo; Aniela Jakubowski; Pilar Justo; Luis M Blanco-Colio; Marta Ruiz-Ortega; Jesús Egido; Alberto Ortiz Journal: J Cell Mol Med Date: 2009-05-01 Impact factor: 5.310
Authors: Ruth Dubin; Yongmei Li; Joachim H Ix; Michael G Shlipak; Mary Whooley; Carmen A Peralta Journal: Am Heart J Date: 2012-02 Impact factor: 4.749
Authors: Meyeon Park; Eric Vittinghoff; Peter Ganz; Carmen A Peralta; Mary Whooley; Michael G Shlipak Journal: Arterioscler Thromb Vasc Biol Date: 2013-10-31 Impact factor: 8.311
Authors: Valvanera Fernández-Laso; Cristina Sastre; Jose M Valdivielso; Angels Betriu; Elvira Fernández; Jesús Egido; Jose L Martín-Ventura; Luis M Blanco-Colio Journal: Clin J Am Soc Nephrol Date: 2016-01-04 Impact factor: 8.237